Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload

New England Journal of Medicine

Volumn 297, Issue 8, 1977, Pages 418-423

  Propper, Richard D ^a,b   Cooper, Barry ^a,b   Rufo, Robert R ^a,b   Nienhuis, Arthur W ^a,b   Anderson, W French ^a,b   Bunn, H Franklin ^a,b   Rosenthal, Amnon ^a,b   Nathan, David G ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON; ASCORBIC ACID;

DOSE RESPONSE; DRUG EXCRETION; DRUG RESPONSE; DRUG URINE LEVEL; HEMOSIDEROSIS; INTRAVENOUS DRUG ADMINISTRATION; IRON URINE LEVEL; PHARMACOKINETICS; SIDEROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THEORETICAL STUDY; URINE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; HUMAN; INSTRUMENTATION; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; THALASSEMIA; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ASCORBIC ACID; CHILD; CHILD, PRESCHOOL; COMPARATIVE STUDY; DEFEROXAMINE; HUMAN; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; IRON; MIDDLE AGE; SIDEROSIS; SUPPORT, U.S. GOV'T, P.H.S.; THALASSEMIA; TIME FACTORS;

EID: 0017622851     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197708252970804     Document Type: Article

References (26)

1. Weintraub LR, Conrad ME, Crosby WH: The treatment of hemochromatosis by phlebotomy. Med Clin North Am 50: 1579–1590, 1966
2. Ellis JT, Schulman I, Smith CH: Generalized siderosis with fibrosis of liver and pancreas in Cooley's (Mediterranean) anemia: with observations on the pathogenesis of the siderosis and fibrosis. Am J Pathol 30: 287–309, 1954
3. Sheldon JH. Haemochromatosis. Lancet 2: 1031–1036, 1934
4. Wyatt JP, Mighton HK, Moragues V: Transfusional siderosis. Am J Pathol 26: 883–897, 1950
5. Fink H: Transfusion hemochromatosis in Cooley's anemia. Ann NY Acad Sci 119: 680–685, 1964
6. Engle MA: Cardiac involvement in Cooley's anemia. Ann NY Acad Sci 119: 694–702, 1964
7. MacDonald RA: Hemochromatosis and Hemosiderosis. Springfield, Illinois, CC Thomas, 1964
8. Buja LM, Roberts WC: Iron in the heart: etiology and clinical significance. Am J Med 51: 209–221, 1971
9. Keberle H: The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 119: 758–768, 1964
10. Fahey JL, Rath CE, Princiotto JV, et al: Evaluation of trisodium calcium diethylenetriaminepentaacetate in iron storage disease. J Lab Clin Med 57: 436–449, 1961
11. Constantoulakis M, Economidou J, Karagiorga M, et al: Combined long-term treatment of hemosiderosis with desferrioxamine and DTPA in homozygous β-thalassemia. Ann NY Acad Sci 232: 193–200, 1974
12. Modell CB, Beck J: Long-term desferrioxamine therapy in thalassemia. Ann NY Acad Sci 232: 201–210, 1974
13. Barry M, Flynn DM, Letsky EA, et al: Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J 2: 16–20, 1974
14. Wapnick A A, Lynch SR, Charlton RW, et al: The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion. Br J Haematol 17: 563–568, 1969
15. O'Brien RT: Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Ann NY Acad Sci 232: 221–225, 1974
16. Nienhuis AW, Delea C, Aamodt R, et al: Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload. Birth Defects 12: 177–185, 1976
17. Propper RD, Shurin SB, Nathan DG: Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294: 1421–1423, 1976
18. Propper RD, Nathan DG, Cooper B, et al: Continuous subcutaneous (SC) infusion of desferrioxamine (DF) in patients with iron (Fe) overload. Blood 48: 964, 1976
19. Propper R, Shurin S, Nathan D: Constant subcutaneous (SC) infusion of desferrioxamine (DF) in transfused beta thalassemia patients (thals). Pediatr Res 10: 380, 1976
20. Denson KW, Bowers EF: The determination of ascorbic acid in white blood cells: a comparison of W.B.C. ascorbic acid and phenolic acid excretion in elderly patients. Clin Sci 21: 157–162, 1961
21. Hwang Y-F, Brown EB: Evaluation of desferrioxamine in iron overload. Arch Intern Med 114: 741–753, 1964
22. Hussain MAM, Flynn DM, Green N, et al: Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 2: 1278–1280, 1976
23. Hussain Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet 1: 977–979, 1977
24. Cumming RLC, Millar JA, Smith JA, et al: Clinical and laboratory studies on the action of desferrioxamine. Br J Haematol 17: 257–263, 1969
25. Gevirtz NR, Wasserman LR: Iron metabolism: studies with desferrioxamine. Am J Clin Nutr 16: 389, 1965
26. Nienhuis AW: Safety of intensive chelation therapy. N Engl J Med 296: 114, 1977